Please assess the completion status of the following clinical trial:

Trial Title: Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degeneration (Wet AMD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients over 50 years of age diagnosed with wet age-related macular degeneration having indication of antiangiogenic therapy.~* Both genders.~* Subjects able to give informed consent.~Exclusion Criteria:~* Patients with contraindication to receive bevacizumab:~  * Hypersensitivity to the active ingredient or to some of the formula excipients.~ * Hypersensitivity to products derived from CHO cells or to other human recombinant antibodies or humanized antibodies.~* Patients having received intravitreal antiangiogenic therapy prior to wet AMD treatment.~* Patients receiving previous systemic antiangiogenic therapy.~* Wet AMD in the healing period or disciform scar.~* Pregnant, breastfeeding or childbearing-aged women.~* Any person with choroidal neovascularization not associated to wet AMD.~* History of retinal or intraocular surgery in the affected eye in the last three months.~* Vitrectomy in the affected eye.~* Any significant ocular infection, active or suspected, having compromised or able to compromise the eye to be studied.~* Ocular inflammatory disease.~* Myopia exceeding -8 diopters.~* Extensive subfoveal subretinal hemorrhage \> 2 papillary diameter (PD).~* Coexistence of other severe ocular diseases: uncontrolled ocular hypertension, terminal glaucoma, diabetic retinopathy, retinal vein thrombosis, optic atrophy.~* History of stroke or myocardial infarction in the last 6 months.~* Patients with coagulopathies.~* Patients physically or mentally disabled to participate in such visual tests.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bevacizumab (Lumiere®) (Type: EXPERIMENTAL): Dosage form: intravitreal single dose vial. Dosage: 0.05ml (1.25 mg) Frequency: monthly injections (up to 6 doses)

Based on this trial design, predict the completion outcome and termination type (if applicable).